MX2022014326A - Proteinas multiespecificas. - Google Patents

Proteinas multiespecificas.

Info

Publication number
MX2022014326A
MX2022014326A MX2022014326A MX2022014326A MX2022014326A MX 2022014326 A MX2022014326 A MX 2022014326A MX 2022014326 A MX2022014326 A MX 2022014326A MX 2022014326 A MX2022014326 A MX 2022014326A MX 2022014326 A MX2022014326 A MX 2022014326A
Authority
MX
Mexico
Prior art keywords
proteins
multispecific proteins
nucleic acids
multispecific
pharmaceutical compositions
Prior art date
Application number
MX2022014326A
Other languages
English (en)
Inventor
Victor Levitsky
Nicolo Rigamonti
Clara Domke
Valérie Perrine Calabro
Smith Pamela Anna Trail
Niina Elisabet Veitonmäki
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2022014326A publication Critical patent/MX2022014326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas multiespecíficas que comprenden dominios diseñados con repeticiones de anquirina con especificidad de unión para diferentes dianas, tales como, por ejemplo, CD40 y FAP. Además, la invención se refiere a ácidos nucleicos que codifican dichas proteínas multiespecíficas, composiciones farmacéuticas que comprenden dichas proteínas multiespecíficas o ácidos nucleicos, y el uso de las citadas proteínas de unión, ácidos nucleicos o composiciones farmacéuticas en métodos para tratar o diagnosticar enfermedades, tales como cáncer, en un mamífero, con inclusión de un ser humano.
MX2022014326A 2020-05-14 2021-05-14 Proteinas multiespecificas. MX2022014326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20174847 2020-05-14
EP20181498 2020-06-22
PCT/EP2021/062860 WO2021229067A1 (en) 2020-05-14 2021-05-14 Multispecific proteins

Publications (1)

Publication Number Publication Date
MX2022014326A true MX2022014326A (es) 2023-02-09

Family

ID=75904957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014326A MX2022014326A (es) 2020-05-14 2021-05-14 Proteinas multiespecificas.

Country Status (13)

Country Link
US (1) US20210395318A1 (es)
EP (1) EP4149959A1 (es)
JP (1) JP2023528204A (es)
KR (1) KR20230022176A (es)
CN (1) CN115768786A (es)
AU (1) AU2021271129A1 (es)
BR (1) BR112022023049A2 (es)
CA (1) CA3178785A1 (es)
CO (1) CO2022017445A2 (es)
IL (1) IL298168A (es)
MX (1) MX2022014326A (es)
TW (1) TW202208408A (es)
WO (1) WO2021229067A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
MX2023010543A (es) 2021-03-09 2023-10-13 Molecular Partners Ag Ligadores multiespecificos de celulas t novedosos basados en darpin.
WO2023110983A1 (en) * 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
MX2019003298A (es) 2016-09-22 2019-09-26 Molecular Partners Ag Proteinas de union recombinantes y sus usos.
CA3053358A1 (en) * 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
KR20210069675A (ko) * 2018-10-01 2021-06-11 에프. 호프만-라 로슈 아게 항-fap 클론 212를 포함하는 이중특이적 항원 결합 분자

Also Published As

Publication number Publication date
EP4149959A1 (en) 2023-03-22
US20210395318A1 (en) 2021-12-23
JP2023528204A (ja) 2023-07-04
TW202208408A (zh) 2022-03-01
CA3178785A1 (en) 2021-11-18
CN115768786A (zh) 2023-03-07
BR112022023049A2 (pt) 2022-12-20
CO2022017445A2 (es) 2023-02-16
AU2021271129A1 (en) 2022-12-15
WO2021229067A1 (en) 2021-11-18
AU2021271129A9 (en) 2023-03-02
IL298168A (en) 2023-01-01
KR20230022176A (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2022014326A (es) Proteinas multiespecificas.
NZ754051A (en) Novel antibodies and uses thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
MX2019001920A (es) Arn la terapia contra el cancer.
PH12017501792A1 (en) Recombinant binding proteins and their use
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
EP4285911A3 (en) Methods and compositions for diagnosis and treatment of cancer
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
MY167232A (en) Polypeptides binding to human complement c5
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
MX349996B (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
UA96279C2 (ru) Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.
ZA202110285B (en) Antibodies and methods of use
MX2023011978A (es) Captadores de cd70 novedosos basados en darpin.